Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

Leukemia

Volumn 29, Issue 11, 2015, Pages 2173-2183

  Morelli, E ^a   Leone, E ^a   Cantafio, M E Gallo ^a   Di Martino, M T ^a   Amodio, N ^a   Biamonte, L ^a   Gulla A ^a   Foresta, U ^a   Pitari, M R ^a   Botta, C ^a   Rossi, M ^a   Neri, A ^b   Munshi, N C ^c,d   Anderson, K C ^c   Tagliaferri, P ^a   Tassone, P ^a,e  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

^e Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CASPASE 10; FLICE INHIBITORY PROTEIN; INTERFERON REGULATORY FACTOR 4; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA 125B; MICRORNA 125B 5P; MYC PROTEIN; UNCLASSIFIED DRUG; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; MICRORNA; MIRN125 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BONE MARROW STROMA CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MIMICRY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NOD SCID MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; INTERFERON REGULATORY FACTORS; MALE; MICE; MICRORNAS; MULTIPLE MYELOMA;

EID: 84946494986     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.124     Document Type: Article

References (51)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
2. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
3. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
4. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 757-767.
5. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
6. Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456-3463.
7. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: immunity. Malignancy! Therapy? Clin Cancer Res 2009; 15: 2954-2961.
8. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W et al. IRF4 addiction in multiple myeloma. Nature 2008; 454: 226-231.
9. Lin FR, Kuo HK, Ying HY, Yang FH, Lin KI. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. Cancer Res 2007; 67: 11914-11923.
10. Lamy L, Ngo VN, Emre NC, Shaffer AL 3rd, Yang Y, Tian E et al. Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell 2013; 23: 435-449.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
12. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
13. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene 2008; 27: S52-S57.
14. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V et al. Mir-34: A new weapon against cancer? Mol Ther Nucleic Acids 2014; 3: e194.
15. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma. Exp Opin Biol Ther 2013; 13: S125-S137.
16. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260-6270.
17. Di Martino MT, Gulla A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PloS One 2014; 9: e89659.
18. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, Amodio N et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013; 4: 242-255.
19. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gulla A et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013; 19: 2096-2106.
20. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012; 3: e436.
21. Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C et al. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol 2014; 229: 2106-2116.
22. Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M et al. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res 2014; 74: 1801-1813.
23. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T et al. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica 2013; 98: 640-648.
24. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105: 12885-12890.
25. Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-381.
26. Rossi M, Amodio N, Di Martino MT, Tagliaferri P, Tassone P, Cho WC. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharma Biotechnol 2014; 15: 459-467.
27. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget 2014; 5: 3039-3054.
28. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gulla A et al. Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. BioMed Res Int 2014; 2014: 217365.
29. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gulla A, Foresta U et al. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PloS One 2014; 9: e90005.
30. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, D'Aquila P et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle 2013; 12: 3650-3662.
31. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K et al. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 2013; 19: 3130-3142.
32. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 2013; 228: 1506-1515.
33. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M et al. DNAdemethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012; 3: 1246-1258.
34. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gulla A et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 838-846.
35. Bader AG. miR-34-A microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120.
36. Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the micronome-using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PloS One 2011; 6: e17429.
37. Gururajan M, Haga CL, Das S, Leu CM, Hodson D, Josson S et al. MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int Immunol 2010; 22: 583-592.
38. Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood 2012; 120: 2450-2453.
39. Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
40. Popowski M, Ferguson HA, Sion AM, Koller E, Knudsen E, Van Den Berg CL. Stress and IGF-I differentially control cell fate through mammalian target of rapamycin (mTOR) and retinoblastoma protein (pRB). J Biol Chem 2008; 283: 28265-28273.
41. Shi Y, Frost P, Hoang B, Benavides A, Gera J, Lichtenstein A. IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1. J Biol Chem 2011; 286: 67-78.
42. Li X, Bian Y, Takizawa Y, Hashimoto T, Ikoma T, Tanaka J et al. ERK-dependent downregulation of Skp2 reduces Myc activity with HGF, leading to inhibition of cell proliferation through a decrease in Id1 expression. Mol Cancer Res 2013; 11: 1437-1447.
43. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
44. Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013; 32: 3071-3079.
45. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26: 2011-2018.
46. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6.
47. Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011; 30: 843-853.
48. Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 2013; 12: 2144-2153.
49. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM et al. MicroRNA-125b potentiates macrophage activation. J Immunol 2011; 187: 5062-5068.
50. So AY, Sookram R, Chaudhuri AA, Minisandram A, Cheng D, Xie C et al. Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. Blood 2014; 124: 1502-1512.
51. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011; 25: 707-711.